Stock listing

Lang & Schwarz:A2DLP7 Gentian Diagnostics ASA Aktie

German listing (Lang & Schwarz) of Gentian Diagnostics ASA · home listing Oslo:GENT

Follow Gentian Diagnostics ASA into a list and get an email when it puts out news.

Home listing price · OSL:GENT

39.60 NOK +0.40 (+1.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OSL:GENT

Past year -27.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
39.20 – 39.60 NOKNov 20, 2026
Volume
50,612 sharesNov 20, 2026
Market cap
612.2M NOKAt the close on Nov 20, 2026 · price × 15.46M shares outstanding
52-week range
33.50 – 60.00 NOKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
225,850 NOKMedian day 2,044 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Gentian Diagnostics ASA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Oslo:GENT · Home39.60 NOK+0.40 (+1.0%)50,61239.2039.6039.2039.20Close on Nov 20, 2026
Frankfurt:6FK€3.63 EUR-0.02 (-0.5%)—€3.63€3.63€3.63€3.65Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OSL:GENT · NOK, adjusted for splits

DayCloseChange%OpenHighLowVolume
39.60+0.40+1.0%39.2039.6039.2050,612
39.200.000.0%39.2039.2039.201,569
39.20-0.60-1.5%40.0040.0039.20788
39.800.000.0%40.0040.0039.209,688
39.800.000.0%39.2039.8039.2027,687
39.80+0.20+0.5%39.5039.8039.206,373
39.60-0.30-0.8%39.0040.1039.009,729
39.900.000.0%39.5039.9039.505,649
39.90+0.80+2.0%40.1040.1038.7051,354
39.10+0.50+1.3%37.6039.1037.60168
38.60-1.30-3.3%39.8039.9038.6013,865
39.90+0.40+1.0%39.4040.0039.404,000
39.50-0.20-0.5%39.4039.5039.401,096
39.70+1.40+3.7%37.6039.8037.602,277
38.30-0.30-0.8%39.4039.4038.2017,441
38.60-0.90-2.3%39.0039.0038.404,198
39.50-0.40-1.0%40.0040.0038.102,792
39.90-0.10-0.3%37.5039.9037.502,741
40.000.000.0%40.1040.1040.00941
40.00+0.40+1.0%39.7040.0038.101,399
39.60+0.70+1.8%40.0040.0039.10650
38.90-1.10-2.8%39.5039.5038.903,323
40.00+0.40+1.0%39.6041.0039.507,583
39.60+1.40+3.7%37.3039.6037.3071
38.20+0.70+1.9%38.5038.8037.302,998
37.50-1.40-3.6%37.5037.5037.40593
38.90-0.30-0.8%43.0043.0038.902,869
39.20+0.70+1.8%38.5039.2037.903,534
38.50-0.50-1.3%38.9038.9037.301,695
39.00+0.50+1.3%38.5039.0037.30787
38.50-0.10-0.3%38.5038.9038.50116
38.60+0.40+1.0%39.4039.9038.609,374
38.20+0.10+0.3%38.6038.6037.802,785
38.10-0.90-2.3%37.1038.1037.00807
39.000.000.0%39.0039.1037.109,609
39.00+2.10+5.7%39.0039.0039.00230
36.90-0.60-1.6%37.2037.2036.906,998
37.50-0.40-1.1%37.5037.5037.50130
37.90-0.40-1.0%38.3038.3037.301,379
38.30+0.40+1.1%37.9038.3037.30816
37.90+0.70+1.9%37.4037.9037.40397
37.20-1.30-3.4%38.9038.9037.2041
38.50-0.50-1.3%39.0039.0038.501,148
39.00-0.20-0.5%39.0039.3039.00845
39.20-0.20-0.5%39.5039.5039.201,000
39.40-0.10-0.3%38.8039.4038.80102
39.50+1.00+2.6%38.5039.5038.50796
38.500.000.0%38.8040.0038.5018,390
38.50-0.90-2.3%39.0039.0038.501,810
39.400.000.0%39.4039.4039.4055
39.40-0.60-1.5%40.0040.0038.40483
40.000.000.0%40.0040.0040.0016,154
40.00+2.10+5.5%37.3040.0037.2016,154
37.90-0.60-1.6%38.4038.5037.2013,763
38.50-0.60-1.5%38.9038.9038.001,310
39.10+1.20+3.2%37.5039.1037.504,337
37.90-1.10-2.8%38.5038.5037.601,000
39.000.000.0%38.5039.0038.502,769
39.00-0.60-1.5%39.3039.3038.7092
39.60-0.10-0.3%38.6039.6038.507,886
39.700.000.0%39.8039.8039.601,100
39.70+0.70+1.8%39.0040.0038.504,537
39.00+0.50+1.3%38.9039.0038.501,090
38.50-0.30-0.8%38.5038.5038.409,685
38.80+1.20+3.2%37.6038.8037.601,049
37.60-1.40-3.6%39.0039.0037.002,916
Ticker
Lang & Schwarz:A2DLP7
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All Gentian Diagnostics ASA news

Gentian Diagnostics ASA on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
19 in the last 12 months · 30 in all · newest Jul 9, 2026 · oldest 2024
Decks
32 decks · latest Oct 20, 2026

Where Gentian Diagnostics ASA is listed

ListingExchangeCountryCurrency
Oslo:GENT · Home listingOsloNorwayNOK
Stockholm:GENTOStockholmSwedenNOK
LS Exchange:A2DLP7LS ExchangeGermanyEUR
Lang & Schwarz:A2DLP7 · This pageLang & SchwarzGermanyEUR
Frankfurt:6FKFrankfurtGermanyEUR
Dusseldorf:6FKDusseldorfGermanyEUR
Stuttgart:6FKStuttgartGermanyEUR

Valuation

EV/sales 2.7× against a median of 3.0×: 6th lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
520.8M NOK
P/E
Loss
EV/sales
2.7×
EV/EBITDA
38.0×
Price/book
3.2×
Gross margin
56.8%
Operating margin
−1.1%
Net margin
−2.6%
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Gentian Diagnostics ASA · OSL:GENTUS$62.79MUS$53.42Mn/a2.7×38.0×3.2×−2.6%0.0×n/a
Seer, Inc. · NASDAQ:SEERUS$75.91M−US$58.25Mn/a−4.1×n/a0.4×−450.9%0.1×1.03
Selvita SA · GPW:SLVUS$75.24MUS$113.4Mn/a1.4×9.1×1.0×−0.6%0.5×n/a
Sera Prognostics, Inc. · NASDAQ:SERAUS$69.65MUS$28.84Mn/a300×n/a1.3×n/a0.1×0.57
BioPorto A/S · OMXCOP:BIOPORUS$68.30MUS$58.06M53.8×10.7×n/a5.7×23.3%0.1×n/a
Nanoform Finland Oyj · OMXHEX:NANOFHUS$66.63MUS$52.80Mn/a11.9×n/a1.7×−339.1%0.2×n/a
Applied BioCode Corp. · TWSE:6598US$64.88MUS$49.53Mn/a2.5×n/a3.0×−7.3%0.1×n/a
Insight Molecular Diagnostics Inc. · NASDAQ:IMDXUS$64.53MUS$55.70Mn/a28.3×n/an/an/an/a1.77
Prestige Biologics Co., Ltd. · KRX:334970US$61.06MUS$72.08Mn/a3.6×n/a0.9×−192.1%0.2×n/a
Champions Oncology, Inc. · NASDAQ:CSBRUS$60.41MUS$56.05Mn/a0.9×168×15.5×−1.9%0.0×0.40
DreamCIS, Inc. · KRX:223250US$60.13MUS$33.21M246×0.6×5.4×1.1×0.4%0.0×n/a
Median of the othersUS$65.75MUS$54.25M150×3.0×9.1×1.3×−4.6%0.1×0.80

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
60.00 NOK · Analysts' mean
EPS, year to Dec 2026
1.90 · 1 analyst
Revenue, year to Dec 2026
198M · 1 analyst

Team and board

OfficerRole
Njaal KindCFO

Events

QuarterResultsShare move
Q3 2026Oct 20, 2026−1.8%
Q2 2026Jul 10, 2026−2.8%
Q1 2026May 7, 2026−2.3%
Q4 2025Feb 12, 2026−29.6%
Q3 2025Oct 24, 2025+3.0%
Q2 2025Jul 11, 2025−4.8%
Q1 2025May 7, 2025 · Before open+8.1%
Q4 2024Feb 12, 2025 · Before open+2.5%
Q3 2024Oct 31, 2024−6.8%
Q2 2024Aug 29, 2024 · Before open−0.9%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 30, 2024 · Before open+2.5%
Q4 2023Feb 9, 2024 · Before open−2.6%
Q3 2023Oct 26, 2023−2.2%
Q2 2023Aug 24, 2023−1.1%
Q1 2023May 5, 2023 · Before open0.0%
Q4 2022Feb 16, 2023 · Before open+1.2%
Q3 2022Oct 27, 2022 · Before open+4.5%
Q2 2022Aug 25, 2022 · Before open+1.6%
Q1 2022Apr 28, 2022 · Before open−6.5%
Q4 2021Feb 17, 2022 · Before open−9.2%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings35 slidesOct 20, 2026
Q2 2026 Earnings PresentationEarnings33 slidesJul 9, 2026
Q1 2026 Earnings PresentationEarnings35 slidesMay 6, 2026
Q4 2025 Earnings PresentationEarnings37 slidesFeb 11, 2026
DNB Nordic Healthcare Conference 2025Conference24 slidesNov 25, 2025
Q3 2025 Earnings PresentationEarnings35 slidesOct 23, 2025
Q2 2025 Earnings PresentationEarnings35 slidesJul 10, 2025
Q1 2025 Earnings PresentationEarnings35 slidesMay 7, 2025
Q4 2024 Earnings PresentationEarnings36 slidesFeb 12, 2025
Q3 2024 Earnings PresentationEarnings33 slidesOct 31, 2024
All 32 decks
DeckKindSlidesDate
Q2 2024 Earnings PresentationEarnings30 slidesAug 29, 2024
Q1 2024 Earnings PresentationEarnings31 slidesApr 30, 2024
Q4 2023 Earnings PresentationEarnings25 slidesFeb 9, 2024
DNB Nordic Healthcare Conference 2023Conference17 slidesDec 14, 2023
Q3 2023 Earnings PresentationEarnings25 slidesOct 26, 2023
Q2 2023 Earnings PresentationEarnings26 slidesAug 24, 2023
Investor Day (May 2023)Investor day70 slidesMay 10, 2023
Q1 2023 Earnings PresentationEarnings23 slidesMay 5, 2023
Q4 2022 Earnings PresentationEarnings29 slidesFeb 16, 2023
Q3 2022 Earnings PresentationEarnings29 slidesOct 27, 2022
Redeye Diagnostics conference 2022Conference11 slidesSeptember 2022
Q2 2022 Earnings PresentationEarnings29 slidesAug 25, 2022
Q1 2022 Earnings PresentationEarnings27 slidesApr 28, 2022
Q4 2021 Earnings PresentationEarnings20 slidesFeb 17, 2022
Q3 2021 Earnings PresentationEarnings58 slidesOct 21, 2021
Q2 2021 Earnings PresentationEarnings36 slidesAug 25, 2021
Investor Presentation (June 2021)Investor deck34 slidesJune 2021
Q1 2021 Earnings PresentationEarnings29 slidesApr 16, 2021
Q4 2020 Earnings PresentationEarnings30 slidesFeb 11, 2021
Pareto Healthcare Conference 2020Conference17 slidesSep 2, 2020
DNB Nordic-American Life Science Conference 2019Conference27 slidesDec 5, 2019
Investor Presentation (December 2016)Investor deck22 slidesDec 14, 2016

Open Decks

Financials

Annual, in NOK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue176.5M152.1M135.2M101.6M83.1M68.4M48.0M46.1M35.0M30.9M
Cost of revenue78.3M69.3M70.9M52.6M43.2M32.6M25.4M6.59M5.79M7.02M
Gross profit98.2M82.8M64.2M49.0M39.9M35.8M22.5M39.5M29.2M23.9M
Research and development23.2M21.9M36.1M24.7M26.8M26.1M19.2M3.80M3.94M2.15M
Selling, general and administrative54.3M21.7M25.1M46.6M38.4M56.2M49.2M18.2M5.96M16.3M
Operating income25.5M15.7M-12.8M-23.2M-22.8M-17.8M-27.2M-20.7M-16.2M-10.1M
Depreciation and amortization9.12M8.96M9.57M10.2M7.35M6.63M6.13M3.90M3.02M2.30M
EBITDA34.6M24.7M-3.20M-13.0M-15.5M-11.2M-21.0M-16.8M-13.2M-7.75M
Interest expense5.22M2.52M3.41M4.21M4.03M550.0K363.0K64.4K19.8K1.34M
Income before tax25.7M20.1M-10.4M-23.6M-24.8M-17.5M-39.8M-19.7M-15.1M-8.93M
Income tax12.4M-25.2M282.0K00-355.0K63.0K63.7K32.9K1.13M
Net income13.3M45.3M45.3M45.3M-24.8M-17.1M-39.9M-19.8M-15.2M-8.93M
Earnings per share, basic86.00294.00-0.69-1.53-1.61-1.11-2.59-1.29-1.08-0.80
Earnings per share, diluted86.00287.00-0.69-1.53-1.61

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents105.9M84.7M87.6M81.6M114.9M157.6M171.2M198.3M145.3M74.3M
Receivables24.3M31.3M17.0M19.2M22.6M15.2M15.5M13.9M12.1M8.25M
Inventory54.1M45.9M37.1M38.5M29.8M20.9M18.2M13.1M11.1M7.55M
Current assets184.3M162.0M141.7M139.3M167.3M193.8M205.0M225.3M170.1M91.8M
Property, plant and equipment4.42M6.26M7.75M9.25M3.36M25.6M7.78M4.74M5.10M4.74M
Goodwill0005.04M5.04M
Total assets258.5M229.7M181.0M187.8M211.8M235.3M227.2M258.0M205.2M123.0M
Accounts payable2.45M6.55M3.71M4.44M4.97M5.81M4.61M3.30M3.55M3.52M
Current liabilities34.1M30.1M25.3M22.0M22.6M22.6M17.0M11.4M8.29M7.42M
Long-term debt0
Total debt10.0M13.0M15.3M22.7M22.3M6.61M698.0K466.2K
Total liabilities53.6M35.6M34.4M33.6M37.0M40.7M18.9M12.1M8.75M7.42M
Shareholders' equity205.0M194.1M146.6M154.2M174.8M194.6M208.2M245.9M196.5M115.5M
Shares outstanding15.4M15.8M15.4M15.4M15.4M15.4M15.4M15.4M14.0M11.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations42.6M13.5M15.5M-14.0M-27.1M-7.66M-21.5M-10.9M-18.6M-7.90M
Capital spending-1.21M-1.38M-955.0K-8.64M-1.02M-6.47M-4.04M-6.15M-6.91M-7.11M
Free cash flow41.4M12.1M14.5M-22.6M-28.1M-14.1M-25.5M-17.0M-25.5M-15.0M
Cash from investing-10.8M-10.9M-4.88M-14.7M-12.8M-4.57M-4.04M-6.15M-6.91M-4.48M
Cash from financing-11.1M-4.95M-4.60M-4.33M-3.12M-1.51M-1.58M68.8M96.5M20.4M
Dividends paid-6.17M0
Share buybacks0570.0K462.0K259.0K68.5M96.1M20.4M
Change in cash20.7M-2.44M5.98M-32.9M-43.0M-13.6M-27.1M51.7M71.0M8.02M

Open Financials

Cap table

Built by 6ix from Gentian Diagnostics ASA’s releases

Common shares
15,458,624
Fully diluted
15,458,624

Fully diluted

LineShares
Common shares15,458,624

Share count over time

CountShares
Nov 22, 202615,458,624

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Njaal KindCFO · Since at least Jul 9, 2026

Open People

Log in to ask 6ix AI your own questions about Gentian Diagnostics ASA.